Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Change in Acquisitions & Divestments (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Change in Acquisitions & Divestments for 4 consecutive years, with $52.3 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Change in Acquisitions & Divestments rose 56.11% year-over-year to $52.3 million, compared with a TTM value of $237.8 million through Dec 2023, up 102.02%, and an annual FY2024 reading of $157.6 million, down 33.75% over the prior year.
  • Change in Acquisitions & Divestments was $52.3 million for Q4 2023 at Terns Pharmaceuticals, up from $41.8 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $92.0 million in Q2 2023 and bottomed at $8.0 million in Q1 2020.
  • Average Change in Acquisitions & Divestments over 4 years is $34.2 million, with a median of $30.8 million recorded in 2022.
  • The sharpest move saw Change in Acquisitions & Divestments grew 10.68% in 2022, then surged 316.83% in 2023.
  • Year by year, Change in Acquisitions & Divestments stood at $8.0 million in 2020, then skyrocketed by 68.92% to $13.5 million in 2021, then soared by 148.14% to $33.5 million in 2022, then soared by 56.11% to $52.3 million in 2023.
  • Business Quant data shows Change in Acquisitions & Divestments for TERN at $52.3 million in Q4 2023, $41.8 million in Q3 2023, and $92.0 million in Q2 2023.